[Form 4] Royalty Pharma plc Insider Trading Activity
Bonnie L. Bassler, a director of Royalty Pharma plc (RPRX), reported a change in beneficial ownership on 09/30/2025. The Form 4 shows an acquisition of 1,047 Class A ordinary shares at a reported price of $35.7872 per share, described as shares issued under the company's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. The filing lists 72,165 shares as the amount of securities beneficially owned following the reported transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Bassler.
Bonnie L. Bassler, una direttrice di Royalty Pharma plc (RPRX), ha segnalato un cambiamento nella proprietà beneficiaria il 30/09/2025. Il Modulo 4 mostra un'acquisizione di 1.047 azioni ordinarie Classe A a un prezzo riportato di $35.7872 per azione, descritte come azioni emesse nell'ambito del Piano di Incentivi Azionari per Direttori Indipendenti 2020 della società in sostituzione di un pagamento di trattenuta trimestrale di $37,500. La dichiarazione elenca 72.165 azioni come l'ammontare di titoli posseduti vantaggiosamente dopo la transazione riportata. Il Modulo 4 è stato firmato da un procuratore ad acta per conto della signora Bassler.
Bonnie L. Bassler, directora de Royalty Pharma plc (RPRX), informó un cambio en la propiedad beneficiosa el 30/09/2025. El Formulario 4 muestra una adquisición de 1,047 acciones ordinarias Clase A a un precio reportado de $35.7872 por acción, descritas como acciones emitidas bajo el Plan de Incentivos en Acciones para Directores Independientes de 2020 de la empresa en lugar de un pago trimestral de honorarios de $37,500. El archivo indica 72,165 acciones como la cantidad de valores poseídos beneficiosamente tras la transacción reportada. El Formulario 4 fue firmado por un poder notarial en nombre de la Sra. Bassler.
Bonnie L. Bassler, Royalty Pharma plc(RPRX)의 이사, 2025년 9월 30일 실질적 소유권 변경을 보고했습니다. Form 4는 1,047주 Class A 일반주를 주당 $35.7872의 보고 가격으로 인수한 것을 보여주며, 이는 회사의 2020년 독립 이사 주식 보상 계획에 따라 발행된 주식으로, 분기별 유지비용 $37,500을 대신해 설명됩니다. 제출서는 거래 후 실질적으로 소유한 증권의 수량으로 72,165주를 기재합니다. Form 4는 Bassler 양을 대신해 대리인이 서명했습니다.
Bonnie L. Bassler, une administratrice de Royalty Pharma plc (RPRX), a signalé un changement de bénéficiaire effectif le 30/09/2025. Le formulaire 4 montre une acquisition de 1 047 actions ordinaires de classe A à un prix déclaré de $35,7872 par action, décrites comme des actions émises dans le cadre du Plan d'incitation en actions pour administrateurs indépendants 2020 de la société, en lieu d'un paiement trimestriel de retenue de $37 500. Le dépôt indique 72 165 actions comme le montant des valeurs détenues avantageusement à la suite de la transaction reportée. Le formulaire 4 a été signé par un mandataire au nom de Mme Bassler.
Bonnie L. Bassler, eine Direktorin von Royalty Pharma plc (RPRX), meldete am 30.09.2025 eine Veränderung der wirtschaftlich Berechtigten. Das Formular 4 zeigt den Erwerb von 1.047 Class A Stammaktien zu einem gemeldeten Preis von $35.7872 pro Aktie, beschrieben als Aktien, die im Rahmen des 2020 Independent Director Equity Incentive Plan des Unternehmens ausgegeben wurden, statt einer vierteljährlichen Retainerzahlung von $37.500. Die Einreichung listet 72.165 Aktien als den Betrag der wirtschaftlich Berechtigten nach der gemeldeten Transaktion. Das Formular 4 wurde von einem Bevollmächtigten im Namen von Frau Bassler unterzeichnet.
فوني L. باسلر، مديرة في Royalty Pharma plc (RPRX)، أبلغت عن تغير في الملكية المستفيدة في 30/09/2025. يبيّن النموذج 4 اكتساب 1,047 سهماً عاديًا من الفئة A بسعر مُبلغ عنه قدره $35.7872 للسهم، موصوفة بأنها أسهم صدرت بموجب خطة حوافز الأسهم لإداريين مستقلين 2020 للشركة كتبديل عن دفعة الرسـوم الفصلية البالغة $37,500. يذكر الملف 72,165 سهماً كمقدار الأوراق المالية المملوكة مستفيداً بعد المعاملة المبلغ عنها. تم توقيع النموذج 4 من قبل وكيل نيابة عن السيدة باسلر.
Bonnie L. Bassler，Royalty Pharma plc（RPRX）的董事，于 2025-09-30 披露了实益所有权变动。 Form 4 显示以每股 $35.7872 的披露价格增持 1,047 股 A 类普通股，被描述为公司在 2020 年独立董事股权激励计划 下发行的股票，以代替季度保留金 $37,500 的支付。申报中列出在所报告交易后实益拥有的证券数量为 72,165 股。 Form 4 由代表 Bassler女士的代理人签署。
- Director alignment with shareholders: Award received under the 2020 Independent Director Equity Incentive Plan, tying compensation to company equity
- Transparent disclosure: Form 4 specifies the grant amount (1,047 shares), price ($35.7872), and that it substituted a $37,500 quarterly retainer
- None.
Insights
TL;DR: Routine director equity award reported; small granted amount relative to typical institutional holdings, likely immaterial to company valuation.
The filing documents a non-derivative acquisition of 1,047 Class A ordinary shares by Director Bonnie L. Bassler under the issuer's director equity plan, received in lieu of a $37,500 quarterly retainer. The transaction price is shown as $35.7872 per share and the post-transaction beneficial ownership is reported as 72,165 shares. This is a standard compensation-related issuance to a director rather than an open-market purchase or sale and does not indicate active trading or a change in control. Materiality appears limited based on the nature and size of the grant.
TL;DR: Typical director compensation disclosure; reflects equity-based retainer, consistent with governance best practices for alignment.
The Form 4 discloses shares issued under the 2020 Independent Director Equity Incentive Plan as compensation for board service. Receiving shares in lieu of cash retainers is a common governance practice to align director interests with shareholders. The report was executed by an attorney-in-fact and includes an explicit explanatory remark about the award. No departures, resignations, or other governance events are disclosed in this filing.
Bonnie L. Bassler, una direttrice di Royalty Pharma plc (RPRX), ha segnalato un cambiamento nella proprietà beneficiaria il 30/09/2025. Il Modulo 4 mostra un'acquisizione di 1.047 azioni ordinarie Classe A a un prezzo riportato di $35.7872 per azione, descritte come azioni emesse nell'ambito del Piano di Incentivi Azionari per Direttori Indipendenti 2020 della società in sostituzione di un pagamento di trattenuta trimestrale di $37,500. La dichiarazione elenca 72.165 azioni come l'ammontare di titoli posseduti vantaggiosamente dopo la transazione riportata. Il Modulo 4 è stato firmato da un procuratore ad acta per conto della signora Bassler.
Bonnie L. Bassler, directora de Royalty Pharma plc (RPRX), informó un cambio en la propiedad beneficiosa el 30/09/2025. El Formulario 4 muestra una adquisición de 1,047 acciones ordinarias Clase A a un precio reportado de $35.7872 por acción, descritas como acciones emitidas bajo el Plan de Incentivos en Acciones para Directores Independientes de 2020 de la empresa en lugar de un pago trimestral de honorarios de $37,500. El archivo indica 72,165 acciones como la cantidad de valores poseídos beneficiosamente tras la transacción reportada. El Formulario 4 fue firmado por un poder notarial en nombre de la Sra. Bassler.
Bonnie L. Bassler, Royalty Pharma plc(RPRX)의 이사, 2025년 9월 30일 실질적 소유권 변경을 보고했습니다. Form 4는 1,047주 Class A 일반주를 주당 $35.7872의 보고 가격으로 인수한 것을 보여주며, 이는 회사의 2020년 독립 이사 주식 보상 계획에 따라 발행된 주식으로, 분기별 유지비용 $37,500을 대신해 설명됩니다. 제출서는 거래 후 실질적으로 소유한 증권의 수량으로 72,165주를 기재합니다. Form 4는 Bassler 양을 대신해 대리인이 서명했습니다.
Bonnie L. Bassler, une administratrice de Royalty Pharma plc (RPRX), a signalé un changement de bénéficiaire effectif le 30/09/2025. Le formulaire 4 montre une acquisition de 1 047 actions ordinaires de classe A à un prix déclaré de $35,7872 par action, décrites comme des actions émises dans le cadre du Plan d'incitation en actions pour administrateurs indépendants 2020 de la société, en lieu d'un paiement trimestriel de retenue de $37 500. Le dépôt indique 72 165 actions comme le montant des valeurs détenues avantageusement à la suite de la transaction reportée. Le formulaire 4 a été signé par un mandataire au nom de Mme Bassler.
Bonnie L. Bassler, eine Direktorin von Royalty Pharma plc (RPRX), meldete am 30.09.2025 eine Veränderung der wirtschaftlich Berechtigten. Das Formular 4 zeigt den Erwerb von 1.047 Class A Stammaktien zu einem gemeldeten Preis von $35.7872 pro Aktie, beschrieben als Aktien, die im Rahmen des 2020 Independent Director Equity Incentive Plan des Unternehmens ausgegeben wurden, statt einer vierteljährlichen Retainerzahlung von $37.500. Die Einreichung listet 72.165 Aktien als den Betrag der wirtschaftlich Berechtigten nach der gemeldeten Transaktion. Das Formular 4 wurde von einem Bevollmächtigten im Namen von Frau Bassler unterzeichnet.
FAQ
What did Bonnie L. Bassler report on Form 4 for RPRX?
Why were the shares issued to the reporting person?
How many shares does Bonnie L. Bassler beneficially own after the transaction?
When was the transaction dated on the Form 4?
Was this a market purchase or a compensation issuance?
